Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
To determine whether the presenilin 1 (PS1), presenilin 2 (PS2) and amyloid beta-protein precursor (APP) mutations linked to familial Alzheimer's disease (FAD) increase the extracellular concentration of amyloid beta-protein (A beta) ending at A beta 42(43) in vivo, we performed a blinded comparison of plasma A beta levels in carriers of these mutations and controls. A beta 1-42(43) was elevated in plasma from subjects with FAD-linked PS1 (P < 0.0001), PS2N1411 (P = 0.009), APPK670N,M671L (P < 0.0001), and APPV7171 (one subject) mutations. A beta ending at A beta 42(43) was also significantly elevated in fibroblast media from subjects with PS1 (P < 0.0001) or PS2 (P = 0.03) mutations. These findings indicate that the FAD-linked mutations may all cause Alzhelmer's disease by increasing the extracellular concentration of A beta 42(43), thereby fostering cerebral deposition of this highly amyloidogenic peptide.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Aβ is produced by sequential β- and γ-secretase proteolytic cleavage of the amyloid precursor protein (APP) [11–17].”
From Amyloid-β interrupts canonical Sonic hedgehog signaling by distorting primary cilia structure (2018) · cites this paper as [11]
In the citing paper
“Similar to PSEN1 , PSEN2 mutations may also cause increased production of long A 𝛃 peptide species (481, 523), although this needs more investigation.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [523]
In the citing paper
“It is well established that this mutation causes concomitant increases in secreted A42 and A40 (Cai et al., 1993;Citron et al., 1994;Scheuner et al., 1996).”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In a previous study of human plasma (Scheuner et al., 1996), we showed that the Swedish APP K670N,M671L mutation increases both A42 and A40 and that other FAD-linked APP, PS1, and PS2 mutations selectively increase A42.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
In the citing paper
“In that report, we suggested that cerebral A deposition in FAD occurs because of an increase in CNS A that develops as part of a generalized genetic effect that also increases plasma A.”
From Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease (2001) · cites this paper as Scheuner et al., 1996
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Self-citationCloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationCandidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationJarrett, J. T., & Lansbury, P. T. (1993) · Cell · doi:10.1016/0092-8674(93)90635-4 · Cited by 2,178
Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Self-citationJarrett, J. T., Berger, E. P., & Lansbury, P. T. (1993) · Biochemistry · doi:10.1021/bi00069a001 · Cited by 2,022
Amyloid β-peptide is produced by cultured cells during normal metabolism
Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., et al. (1992) · Nature · doi:10.1038/359322a0 · Cited by 1,921
Self-citationCitron, M., Oltersdorf, T., Haass, C., McConlogue, L., Hung, A. Y., Seubert, P., Vigo-Pelfrey, C., Lieberburg, I., & Selkoe, D. J. (1992) · Nature · doi:10.1038/360672a0 · Cited by 1,757
Self-citationIsolation and quantification of soluble Alzheimer's β-peptide from biological fluids
Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schiossmacher, M., Whaley, J., Swindlehurst, C., et al. (1992) · Nature · doi:10.1038/359325a0 · Cited by 1,731
Self-citation
Cited by
Items 2,101–2,200 of 2,576
Wu, Y., Srirajavatsavai, V., Monplaisir, K. M., Sambanthamurthi, R., & Gupta, S. V. (2015) · The FASEB Journal · doi:10.1096/fasebj.29.1_supplement.271.8 · Cited by 3
Leissring, M. A., & Saido, T. C. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_10 · Cited by 3
The involvement of neuronal chloride transporter deficiencies in epilepsy
Sullivan, B. J., & Kadam, S. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-815318-5.00014-5 · Cited by 4
The Presenilins and Alzheimer Disease
Lévesque, G., & George‐Hyslop, P. S. (2020) · McGill Journal of Medicine · doi:10.26443/mjm.v3i2.542 · Cited by 3
Genetics of Alzheimer's Disease
Honig, L. S. (1997) · Perspectives on Neurophysiology and Neurogenic Speech and Language Disorders · doi:10.1044/nnsld7.4.6 · Cited by 3
Presenilin immunoreactivity in Alzheimer's disease
Panegyres, P. K., & Toufexis, K. (2005) · European Journal of Neurology · doi:10.1111/j.1468-1331.2005.01050.x · Cited by 3
“Cell lines expressing PS1 mutations produce more long Ab than controls consistent with the concept of a toxic gain of function (Scheuner et al., 1996; Citron et al., 1997).”
BackgroundNovel presenilin 1 mutation associated with early-onset Alzheimer’s disease in a Saudi patient
Al-Khedhairy, A. A., Bin-Dukhyil, A.-A. A., Arfin, M., ., B. A. A., Al‐Rajeh, S., & Aljumah, M. (2005) · Neurosciences · doi:10.17712/1658-3183.1372 · Cited by 3
Genes implicated in the pathogenesis of Alzheimer s disease
Das, H. K. (1997) · Frontiers in bioscience · doi:10.2741/a188 · Cited by 4
Aging-Related Memory Disorders—Alzheimer’s Disease
Sweatt, J. D. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374951-2.00012-3 · Cited by 5
Aging-Related Memory Disorders
Sweatt, J. D. (2003) · Elsevier eBooks · doi:10.1016/b978-012678957-7/50013-x · Cited by 3
Cognitive Impairment and Rehabilitation in Alzheimer’s Disease
Angelopoulos, T., Scordilis, D. M., & Tsagkaris, C. (2019) · Springer eBooks · doi:10.1007/978-981-13-9636-6_1 · Cited by 5
Substrate-based chemical probes for Alzheimer’s γ-secretase
Wolfe, M. S. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02565-w · Cited by 4
“…of Medicinal Chemistry, University of Kansas, 1567 Irving Hill Road, GLH-2115, Lawrence, KS 66045, USA 12 34 56 78 90 () ;,: 12 34 56 78 90 (); ,: Scheuner et al. 1996; Citron et al. 1997), and knockout of PSEN1 dramatically reduced Aβ production from APP at the level of γ-secretase (De…”
BackgroundMayeux, R. P., & Gandy, S. (2000) · Elsevier eBooks · doi:10.1016/b978-012288145-9/50112-1 · Cited by 3
Beta Amyloid Protein Clearance and Microglial Activation
Frautschy, S. A., Cole, G. M., & Ard, M. D. (2002) · Springer eBooks · doi:10.1007/978-1-4757-4139-1_12 · Cited by 3
Weggen, S., Czirr, E., Leuchtenberger, S., & Eriksen, J. L. (2007) · Springer eBooks · doi:10.1007/978-0-387-71522-3_11 · Cited by 4
Syndromes and Diseases Associated with the Notch Signalling Pathway
Turnpenny, P. D. (2014) · Wiley eBooks · doi:10.1002/9780470015902.a0024870 · Cited by 3
Predicting Who Will Develop Alzheimer’s Disease
Mayeux, R. P. (1999) · Springer eBooks · doi:10.1007/978-3-642-60076-0_2 · Cited by 7
Toward Personalized Cell Therapies by Using Stem Cells
Isobe, K.-I., Cheung, H. S., & Wu, J. (2012) · BioMed Research International · doi:10.1155/2012/172564 · Cited by 3
Gandy, S. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.01.003 · Cited by 3
Neuronal models to study amyloid precursor protein expression and processing in vitro
Annaert, W. G., & Strooper, B. D. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/s0925-4439(00)00032-6 · Cited by 5
Inflammation-associated risk factors for Alzheimer s disease and dementia
Eriksson, U. K. (2010) · Figshare · Cited by 3
Paganetti, P., & Staufenbiel, M. (2003) · Humana Press eBooks · doi:10.1385/1-59259-195-7:239 · Cited by 3
Roberson, E. D., & Kao, A. W. (2016) · Cambridge University Press eBooks · doi:10.1017/9781139924771.007 · Cited by 3
Sialic Acid Conjugated Chitosan for the Attenuation of Amyloid-beta Toxicity
Dhavale, D. D. (2009) · Louisiana State University · doi:10.31390/gradschool_theses.3810 · Cited by 4
Amyloid-β Hypothesis of Alzheimer’s Disease
Shearman, M. S. (1998) · Advances in behavioral biology · doi:10.1007/978-1-4615-5337-3_27 · Cited by 3
Identification of Peptides Binding to Presenilin 1 by Screening of Random Peptide Display Libraries
Schwarzman, A. L., Tsiper, M. V., Vitek, M. P., George‐Hyslop, P. S., & Goldgaber, D. (1998) · Advances in behavioral biology · doi:10.1007/978-1-4615-5337-3_20 · Cited by 3
Early-Onset Alzheimer’s disease and amyloid precursor protein gene mutations
Varte, V., Ralte, L., & Kumar, N. S. (2025) · Discover Neuroscience · doi:10.1186/s13064-025-00203-y · Cited by 7
Nakamura, R., Okada, M., Takahashi, A., Hayashi, Y., Konishi, M., Ito, F., Murakami, I., Saito, M., & Akizawa, T. (2025) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2025.09.001 · Cited by 2
Nashiro, K., Cahn, B. R., Choi, P., Lee, H. R. J., Satchi, S., Min, J., Yoo, H. J., Cho, C., Mercer, N., Sordo, L., et al. (2025) · Psychophysiology · doi:10.1111/psyp.70182 · Cited by 2
“Plasma A β 40 and A β 42 levels are elevated in people with genetic risk of AD before onset of disease symptoms (Coppus et al. 2012; Ertekin-Taner et al. 2000, 2008; Head et al. 2011; Scheuner et al. 1996; Tokuda et al. 1997).”
The aggregation of amyloid-β: from condensation, nucleation, and conformation to targeting therapy
Chen, B., Chen, T., Sun, Z., Liu, L., Jia, Y., Ji, Y., Wang, J., Sun, F., & Huang, Y. (2026) · Life Sciences · doi:10.1016/j.lfs.2026.124397 · Cited by 3
Genetic and Epigenetic Architecture of Alzheimer’s Dementia
Cervera‐Carles, L., & Clarimón, J. (2016) · Current Genetic Medicine Reports · doi:10.1007/s40142-016-0086-1 · Cited by 4
The Importance of Olfactory and Motor Endpoints for Zebrafish Models of Neurodegenerative Disease
Shamchuk, A. L., & Tierney, K. B. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415894-8.00027-0 · Cited by 3
Epigenetic regulons in Alzheimer's disease
Raval, M., Mishra, S., & Tiwari, A. K. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.01.012 · Cited by 2
Du, J., Xu, G., Zhang, W., Cong, J., Si, X., & Wei, B. (2024) · SAR and QSAR in environmental research · doi:10.1080/1062936x.2024.2419911 · Cited by 2
“Sequential proteolytic cleavage of the amyloid precursor protein (APP) by β-amyloid cleavage enzyme 1 (BACE1) and γ-secretase produces Aβ peptide [8–14].”
Coffee “Breaks” Alzheimer's Disease
Tabaton, M. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-1089 · Cited by 2
“derly subjects at risk of AD, on aMCI, as well as on AD mice [18–20], suggest that Aβ in plasma reflects Aβ”
El péptido β-amiloide: mecanismos de neurotoxicidad. neuroprotección por antioxidantes y estrógenos
López, F. J. M. (2001) · Revista Española de Geriatría y Gerontología · doi:10.1016/s0211-139x(01)74694-x · Cited by 5
Tarasov, A. S., Зуфарович, Р. И., Blokhin, D. S., Klochkov, A. V., Il'yasov, K. A., & Klochkov, V. V. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.100762 · Cited by 2
Animal Models of Alzheimer’s Disease
Kiyota, T. (2013) · Springer protocols handbooks/Springer protocols · doi:10.1007/978-1-4614-8794-4_35 · Cited by 3
The Biological Significance of Neuropathological Lesions in Alzheimer’s Disease
Mori, H. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00050-x · Cited by 2
Fisiopatología de la enfermedad de Alzheimer
Delacourte, A. (2002) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(02)70234-1 · Cited by 8
Li, Q., & Masters, C. L. (2007) · Elsevier eBooks · doi:10.1016/b978-012369367-9/50805-3 · Cited by 2
Endogenously generated amyloid β increases membrane fluidity in neural 2a cells
Niu, Y., Sheng, B., Song, B., Liu, L., Zhang, X., Zhao, N., & Gong, Y. (2009) · 中国科学通报:英文版 · doi:10.1007/s11434-008-0527-7 · Cited by 2
Neurodegenerative Diseases and Dementia
Janus, C., & Welzl, H. (2016) · Springer eBooks · doi:10.1007/978-1-4939-3777-6_6 · Cited by 2
Frost, G. R., Wong, E., & Li, Y. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707809114 · Cited by 4
The Importance of Olfactory and Motor Endpoints for Zebrafish Models of Neurodegenerative Disease
Shamchuk, A. L., Allison, W. T., & Tierney, K. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809468-6.00021-8 · Cited by 3
Introduction to Alzheimer’s Disease
Manivasagam, T., Surya, R., Jayalakshmi, M., Thenmozhi, A. J., Prema, A., Qoronfleh, M. W., Alharbi, H. F., & Rajamani, Y. (2023) · Nutritional neurosciences · doi:10.1007/978-981-99-0677-2_1 · Cited by 3
Mattson, M. P., Pedersen, W. A., & Culmsee, C. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-106-0_6 · Cited by 2
The Role of the Presenilins in Alzheimer's Disease
Tanzi, R. E. (1998) · Elsevier eBooks · doi:10.1016/b978-012734610-6/50010-5 · Cited by 2
Self-citationEtiology, Genetics, and Pathogenesis of Alzheimer's Disease
McKeon‐O'Malley, C., & Tanzi, R. E. (2001) · Elsevier eBooks · doi:10.1016/b978-012351830-9/50024-x · Cited by 4
Self-citationPresenilin-2 in the cynomolgus monkey brain: investigation of age-related changes
Kimura, N., Nakamura, S. I., Ono, F., Sakakibara, I., Ishii, Y., Kyuwa, S., & Yoshikawa, Y. (2004) · Primates · doi:10.1007/s10329-004-0076-x · Cited by 3
Biochemical heterogeneity of Alzheimer's disease
Shoji, M., & Harigaya, Y. (1998) · Neuropathology · doi:10.1111/j.1440-1789.1998.tb00088.x · Cited by 2
Dean, E. (2008) · Eukaryon · Cited by 4
Kubo, T., Nishimura, S., Murasugi, T., Kaneko, I., Meguro, M., Marumoto, S., Kogen, H., Koyama, K., Oda, T., & Nakagami, Y. (2003) · Pharmacology & Toxicology · doi:10.1111/j.1600-0773.2003.pto930603.x · Cited by 2
Anthracyclines and Amyloidosis
Post, C., Tagliavini, F., McArthur, R. A., Vedova, F. D., Gerna, M., Bandiera, T., Varasi, M., Molinari, A., & Lansen, J. (1998) · Advances in behavioral biology · doi:10.1007/978-1-4615-5337-3_29 · Cited by 2
Genes associated with Alzheimer Disease
Munshi, A., & Ahuja, Y. R. (2010) · Cited by 4
Ng, J., Aguilar, M., & Small, D. H. (2006) · Springer eBooks · doi:10.1007/978-1-84628-440-3_6 · Cited by 2
Aβ-Induced Proinflammatory Cytokine Release from Differentiated Human THP-1 Monocytes
Brunden, K. R., Kocsis‐Angle, J., Embury, P., & Yates, S. L. (2003) · Humana Press eBooks · doi:10.1385/1-59259-195-7:101 · Cited by 2
Origin(s) of Intraneuronal Amyloid
D’Andrea, M. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804256-4.00002-4 · Cited by 2
Tam, J. H. K., & Pasternak, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801942-9.00004-5 · Cited by 4
Mouse Model for Alzheimer’s Disease
Chishti, M. A., & Nakeeb, S. M. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-285-4_22 · Cited by 2
Genetics of Alzheimer’s Disease and Related Disorders
Hardy, J. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-661-4_1 · Cited by 2
Self-citationAspartic Proteases of Alzheimer’s Disease: β- and γ-Secretases
Wolfe, M. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-394447-4.10077-x · Cited by 2
Ahmed, A. (2013) · Digital Commons - URI (University of Rhode Island) · doi:10.23860/thesis-ahmed-aseef-2013 · Cited by 4
Beyreuther, K. T., & Masters, C. L. (2001) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-662-04399-8_7 · Cited by 2
Proteolytic Processing of the Amyloid Precursor Protein of Alzheimer’s Disease
Lichtenthaler, S. F., Masters, C. L., & Beyreuther, K. T. (2000) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-57092-6_19 · Cited by 2
Cytosolic protein‐protein interactions that regulate the amyloid precursor protein
Sabo, S. L., & Ikin, A. F. (2002) · Drug Development Research · doi:10.1002/ddr.10078 · Cited by 2
“In addition, production of Ab42 appears to be specifically enhanced by some mutations that cause AD [Suzuki et al., 1994; Tamaoka et al., 1994; Borchelt et al., 1996; Citron et al., 1996; Duff et al., 1996; Lemere et al., 1996; Scheuner et al., 1996].”
Kametani, F., Tanaka, K., Usami, M., Maruyama, K., & Mori, H. (2001) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(01)00543-3 · Cited by 2
Molecular Genetics of the Presenilins in Alzheimer’s Disease
Fraser, P. E., Yu, G., Lévesque, G., Ikeda, M., Nishimura, M., Rogaeva, E. A., Westaway, D. A., George‐Hyslop, P. S., & Carlson, G. A. (1998) · Springer eBooks · doi:10.1007/978-3-642-72103-8_1 · Cited by 2
Usefulness of Cerebrospinal Fluid Biomarkers in Diagnosis of Early Alzheimer's Disease
Herukka, S. (2007) · Cited by 2
Calder√≥n-GarciduenÀúas, L., & Reed, W. (2006) · Informa Healthcare eBooks · doi:10.1201/9781420003147.ch19 · Cited by 2
Are Late-Onset Autosomal Dominant and Sporadic Alzheimer Disease “Separate but Equal”?
Ringman, J. M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.1633 · Cited by 2
Knopman, D. S., Ritchie, K. A., Polge, C., Alafuzoff, I. I., & Soininen, H. S. (2003) · Wiley eBooks · doi:10.1002/9780470752340.ch19 · Cited by 3
Current and Developing Methods for Diagnosing Alzheimer's Disease
Fuller, S. J., Carrigan, N., Sohrabi, H. R., & Martins, R. N. (2019) · Wiley eBooks · doi:10.1002/9781119356752.ch3 · Cited by 2
Presenilins and Alzheimer’s disease: the role of Aβ42
Eckman, C. B. (1998) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6467-9_16 · Cited by 2
Self-citationSignaling by β-Amyloid Precursor Protein
Furukawa, K. (1998) · Humana Press eBooks · doi:10.1007/978-1-59259-475-7_11 · Cited by 2
Han, J.-Y., Park, M., & Lee, H. (2023) · Molecular & Cellular Toxicology · doi:10.1007/s13273-023-00399-2 · Cited by 1
“In particular, Aβ 1–42 is highly neurotoxic, and its overproduction is closely related to AD (Scheuner et al. 1996).”
PSEN2 Mutations May Mimic Frontotemporal Dementia: Two New Case Reports and a Review
Pereiro, A. M. M., Castro, B. Q., Ouro, A., Aldrey, J. M., Hernández, J. C., Aramburu-Núñez, M., Arias, M., Martín, I. J., Sobrino, T., & Peleteiro, J. M. P. (2024) · Biomedicines · doi:10.3390/biomedicines12081881 · Cited by 1
“Regarding the non-decreased amyloid 1–42 values in case A, we hypothesize that this is a pathological amyloid-hyperproducing patient [28,29].”
BackgroundPathophysiologic abnormalities in transgenic mice carrying the Alzheimer disease PSEN1 Δ440 mutation
Fuller, P. E., Collis, V. L., Sharma, P., Burkett, A. M., Wang, S., Brown, K. A., Weir, N., Goulbourne, C. N., Nixon, R. A., Longden, T. A., et al. (2024) · Human Molecular Genetics · doi:10.1093/hmg/ddae139 · Cited by 1
McFarlane, O., Kozakiewicz, M., Kędziora–Kornatowska, K., Gałęska-Śliwka, A., & Wojciechowska, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47030203 · Cited by 1
“…the results showing lack of signi fi cant di ff erences in plasma A β 42 levels in cognitive norm subjects compared to subjects with sporadic AD [34–37], as well as the latest longitudinal studies reporting no di ff erences in plasma concentrations of free A β 42 between subjects with…”
Cerebrospinal Fluid Biomarkers of Alzheimer Disease
Васильевна, Н. К., Shpilyukova, Y. A., Шабалина, А. А., Fedotova, E. Y., & Illarioshkin, S. N. (2025) · Annals of Clinical and Experimental Neurology · doi:10.17816/acen.1185 · Cited by 1
Anschuetz, A., Listyono, R., Vorley, T., Platt, B., Harrington, C. R., Riedel, G., & Schwab, K. (2026) · Journal of Integrative Neuroscience · doi:10.31083/jin48581 · Cited by 1
APP E590D mutation increases generation of Aβ and Aη peptides and exacerbates tauopathy
Liu, T., Wetzel, L., Roy, D., Zhang, K., Zhu, Z., Kumaraguru, P., Gorthi, V., Jeon, H., Woo, J. A., & Kang, D. E. (2026) · npj Dementia · doi:10.1038/s44400-026-00069-9 · Cited by 1
Nabi, S. U., Rasool, I., Khan, A., Haq, A. U., Hussain, I., Khan, M. S., Majid, S., Rashid, S., Rashid, S. M., Sehar, N., et al. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-025-01781-w · Cited by 1
The γ-secretase complex: from discovery to a therapeutic target
Malvankar, S. R., & Wolfe, M. S. (2026) · RSC Chemical Biology · doi:10.1039/d6cb00022c · Cited by 1
From mechanism to substratome: Unraveling mysteries of γ-secretase
Steiner, H., Breimann, S., Kamp, F., & Frishman, D. (2026) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2026.113287 · Cited by 1
“As a consequence of the reduced processivity imposed by the FAD mutations (26, 96), this results in a relative increase of secreted A β 42 (69, 97) and/or, but less frequently, A β 43 JBC REVIEWS: Mechanism and substratome of γ -secretase (98–100) in the total pool of secreted A β species (Fig.”
Mechanistic Studies of the Effect of Presenilins 1 and 2 on APP Metabolism
Selkoe, D. J., Xia, W., Zhang, J., Podlisny, M. B., Lemere, C. A., Citron, M., & Koo, E. H. (1998) · Springer eBooks · doi:10.1007/978-3-642-72103-8_6 · Cited by 1
Self-citationStover, K. R. (2015) · DalSpace (Dalhousie University) · Cited by 1
Bornebroek, M., Haan, J., Bakker, E., & Roos, R. A. C. (2000) · Springer eBooks · doi:10.1007/978-94-017-1007-7_6 · Cited by 1
Non-Neuronal Cells Exacerbate -Amyloid Aggregation in the Aged Brain
Corbett, G. T., & Buss, E. W. (2014) · Journal of Neuroscience · doi:10.1523/jneurosci.1825-14.2014 · Cited by 1
“These genetic mutations ultimately cause early onset, familial forms of AD (FAD) by elevating the A 42/A 40 ratio and exacerbating A 42 deposition in select forebrain regions, including the hippocampal complex and neocortex (Scheuner et al., 1996).”
BackgroundOmura, Y., Nihrane, A., Lu, D. P., Jones, M. K., Shimotsuura, Y., & Ohki, M. (2015) · Acupuncture & Electro-Therapeutics Research · doi:10.3727/036012915x14381285982921 · Cited by 3
App Localization and Trafficking in the Central Nervous System
Buxbaum, J. D., Ikin, A. F., Luo, Y., Näslund, J., Sabo, S. L., Vincent, B., Watanabe, T., & Greengard, P. (1998) · Advances in behavioral biology · doi:10.1007/978-1-4615-5337-3_70 · Cited by 1
Pietropaolo, S., Sluyter, F., & Crusio, W. E. (2014) · Cambridge University Press eBooks · doi:10.1017/cbo9781107360556.030 · Cited by 1
The Molecular Basis of Alzheimer's Disease
Ingelsson, M., & Hyman, B. T. (2007) · Elsevier eBooks · doi:10.1016/b978-012369509-3.50018-4 · Cited by 1
Biomarkers in vascular dementia
Wallin, A., & Pirttilä, T. (2009) · Cambridge University Press eBooks · doi:10.1017/cbo9780511575976.008 · Cited by 1
Risk Factors for Alzheimer’s Disease
Cai, D., & Gaamouch, F. E. (2016) · InTech eBooks · doi:10.5772/64270 · Cited by 2
“PSEN1 mutations by altering APP γ-secretase cleavage site promote Aβ42 genera‐ tion [68].”
BackgroundStephens, G. S., You, J. C., Fu, C.-H., & Chin, J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.21126-7 · Cited by 1
MOLECULAR GENETICS OF ALZHEIMER DISEASE
Parvathy, S., & Buxbaum, J. D. (2002) · Cited by 2
Herbal Medicinal based Approach for Alzheimer Disease - A Mathematical Model
Komal, A., Khurana, P., & Kumar, D. (2021) · International Journal of Current Research and Review · doi:10.31782/ijcrr.2021.132109 · Cited by 1
The Biology of the Presenilin Complexes
Wakabayashi, T., Iwatsubo, T., & Strooper, B. D. (2007) · Springer eBooks · doi:10.1007/978-0-387-35135-3_3 · Cited by 2
Therapeutic targeting of glycogen synthase kinase-3: Strategy to address neurodegenerative diseases
Noor, S., Raza, A., & Hassan, M. I. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-91287-7.00008-9 · Cited by 3
Metadata
- Authors
- Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., Larson, E., Levy-Lahad, L., Viitanen, M., Peskind, E., Poorkaj, P., Schellenberg, G., Tanzi, R., Wasco, W., Lannfelt, L., Selkoe, D., & Younkin, S.
- Affiliations
- Case Western Reserve University (US)
- Mayo Clinic (US)
- Karolinska Institutet (SE)
- Brigham and Women's Hospital (US)
- Takeda (Japan) (JP)
- University of Washington (US)
- University of South Florida (US)
- Harvard University (US)
- ORCID
- Venue
- Nature Medicine
- Published
- 1996-08
- Volume
- 2
- Issue
- 8
- Pages
- 864-870
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2101077392
- Semantic Scholar
- ce2164647cb7fb8dcec21d95359a92ec9830047a
- Cited by
- 2,599
- References
- 40
- Citations by year
- 2026: 26 · 2025: 34 · 2024: 58 · 2023: 74 · 2022: 45 · 2021: 66 · 2020: 66 · 2019: 58 · 2018: 53 · 2017: 64 · 2016: 76 · 2015: 72 · 2014: 77 · 2013: 91 · 2012: 96
- FWCI
- 102.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Medicine (publishedVersion)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- amyloid-beta, familial Alzheimer's disease, presenilin 1, presenilin 2, amyloid precursor protein, APP mutations, amyloid plaques
- MeSH terms
- Alzheimer Disease, Cells, Cultured, Female, Fibroblasts, Humans, Male, Membrane Proteins, Mutation, Peptide Fragments, Amyloid beta-Peptides, Amyloid beta-Protein Precursor, Culture Media, Conditioned, Presenilin-1, Presenilin-2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.